A $5 million debt payment doubled Tenon Medical’s stock price in two days. The company had negative equity going into that payment. AEON Biopharma spent the same stretch adding another data point to a multi-year case that its botulinum toxin candidate matches BOTOX at the molecular level. Neither story ends with an approved product yet, and both come from companies distressed enough to need saying so plainly.
Tenon Medical Surges Up to 90% After Repaying $5.16 Million in Convertible Notes
Tenon Medical (Nasdaq: TNON) shares jumped as much as 90-95% intraday on September 10-11 after the company announced it had repaid in full its $5.16 million in original issue discount senior convertible notes, ahead of their September 11 maturity date.
The notes, issued in March, carried terms that would have let holders convert debt into stock at a discount to the market price if they were not paid off in cash first. Removing that conversion option eliminated a standing source of potential dilution that had been hanging over the stock.
Tenon sells the Catamaran SI Joint Fusion System, a minimally invasive device for sacroiliac joint disorders. Second-quarter revenue reached $1.28 million, up 127% year-over-year, with gross margin expanding to 64%. The company also received FDA 510(k) clearance for an updated version of the device and reported record surgical case volume in July.
None of that changes how distressed the balance sheet still is. Tenon completed a 1-for-35 reverse stock split on August 10 to regain Nasdaq compliance. Its stockholders’ equity is negative. Shares outstanding have nearly doubled over the past year through repeated dilutive offerings. Market capitalization sits at roughly $4 million-$6 million, among the smallest and most volatile names this section has covered, with a 52-week range running from $2.40 to $50.40 on a split-adjusted basis.
AEON Biopharma Adds Data Supporting ABP-450 as a BOTOX Biosimilar
AEON Biopharma (NYSE American: AEON) reported pilot study results in early September adding to its case that ABP-450 is analytically comparable to BOTOX under the FDA’s biosimilar pathway. The company said the results were not powered for formal statistical comparison and plans a formal multi-lot comparability study in the first half of 2027.
ABP-450 is manufactured by Daewoong Pharmaceutical in a facility already authorized by the FDA, Health Canada, and the European Medicines Agency to produce botulinum toxin products. Earlier analytical data found a 100% amino-acid sequence match to BOTOX across the toxin complex, with sequence coverage of 93-99%. AEON plans to build on this evidence to support an eventual biologics license application rather than run a full traditional clinical program from scratch.
AEON’s own numbers tell a different story than its science. The company’s market capitalization has swung between roughly $5 million and $30 million over the past year depending on the day. An analyst cut a price target on the stock from $5 to $1.20 in August. AEON regained NYSE American listing compliance only weeks before reporting these latest results, and it priced an upsized $13.75 million public offering in June, continuing a pattern of funding operations through equity issuance rather than product revenue.
TNON, AEON: Forward-Looking FAQ
No. Removing the conversion risk on one $5.16 million note does not change the fact that Tenon has negative equity and has relied on repeated dilutive stock offerings to fund operations. Nothing about this repayment guarantees the company will not need to raise more capital again soon.
Not entirely. The FDA’s biosimilar pathway can reduce, but does not eliminate, the need for clinical evaluation. AEON’s own disclosures say subsequent FDA interactions will determine whether residual uncertainty requires at least limited clinical testing before a biologics license application can move forward.
Sources
- SEC EDGAR / ACCESS Newswire: Tenon Medical Announces Early Repayment of its Convertible Notes, September 9, 2026
- Benzinga: Tenon Medical Stock Surges Thursday: What’s Driving the Action?, September 10, 2026
- StockTitan: Tenon Medical (TNON) Stock News & Updates, Q2 2026 results and FDA 510(k) clearance coverage
- Investing.com: AEON reports pilot study results for ABP-450 biosimilar candidate, September 2026
- CNN Markets: AEON Biopharma (AEON) news and analyst activity
Editorial Disclosure
Sources: SEC Form 8-K, company press releases, named financial press. Securities discussed: Tenon Medical, Inc. (Nasdaq: TNON) and AEON Biopharma, Inc. (NYSE American: AEON). aktiego.com has received no compensation from any company, IR firm, or third party mentioned. No aktiego.com staff or principal holds a position in TNON or AEON. Tenon Medical: market cap approximately $4 million-$6 million; completed a 1-for-35 reverse stock split on August 10, 2026; has negative stockholders’ equity; shares outstanding increased significantly over the past year through dilutive offerings; stock is thinly traded and highly volatile. AEON Biopharma: market cap has ranged from approximately $5 million to $30 million over the past year; regained NYSE American listing compliance in 2026; an analyst price target was cut from $5 to $1.20 in August 2026; ABP-450 is an investigational biosimilar candidate with no FDA approval or clearance. AEON’s pilot comparability data was not powered for formal statistical conclusions, per the company’s own disclosure. Both companies are unprofitable, early-commercial or pre-commercial stage, and depend on continued access to capital. Small cap, micro-cap, and nano-cap securities are speculative and carry a high risk of total loss, particularly for thinly traded stocks with recent reverse splits or listing compliance issues. This content is for informational purposes only, is not financial or investment advice, and aktiego.com is not a registered investment advisor. Consult a qualified financial advisor before investing. Full DISCLAIMER
